Close Menu

NEW YORK (360Dx) – Glycomics startup AccuDava is preparing a clinical study for its glycan-based test for predicting patient response to first-line platinum-based chemotherapy in ovarian cancer.

According to Nahid Razi, AccuDava’s founder and CEO, the company is collaborating with the Fred Hutchinson Cancer Research Center (FHCRC) to obtain clinical samples for a study it hopes to complete later this year.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.